Pomired 2mg Capsule

• Multiple myeloma

The human body reacts differently to Pomired 2mg Capsule. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the common side effects of Capsule are mentioned below:

• Fatigue
• Fever
• Nausea
• Constipation
• Breathing problems
• Bone pain
• Muscle cramp
• Diarrhea
• Cough
• Decreased appetite

• Take Pomired 2mg Capsule in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.​
  

• Pomired 2mg Capsule is an anticancer medicine with active ingredient Pomalidomide that is a powerful immunomodulatory anti-cancer drug. It works by by boosting the immune system, stopping new blood vessel formation (angiogenesis), and killing cancer cells directly.
• This medicine helps the bone marrow to produce normal blood cells and kill abnormal cells.​
  

• Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., ... &Zweegman, S. (2021). Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. The Lancet Oncology, 22(6), 801-812.
• Ríos-Tamayo, R., Martín-García, A., Alarcón-Payer, C., Sánchez-Rodríguez, D., de la Guardia, A. M. D. V. D., García Collado, C. G., ... & Cabeza Barrera, J. (2017). Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug design, development and therapy, 2399-2408.
• Dimopoulos, M. A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., ... & Trudel, S. (2024). Belantamabmafodotin, pomalidomide, and dexamethasone in multiple myeloma. New England Journal of Medicine, 391(5), 408-421.
• Fouquet, G., Bories, C., Guidez, S., Renaud, L., Herbaux, C., Javed, S., ... & Leleu, X. (2014). Pomalidomide for multiple myeloma. Expert Review of Hematology, 7(6), 719-731.
• Chanan-Khan, A. A., Swaika, A., Paulus, A., Kumar, S. K., Mikhael, J. R., Rajkumar, S. V., ... & Lacy, M. Q. (2013). Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood cancer journal, 3(9), e143-e143.